



Abgenix Reports Second Quarter 2001 Results

FREMONT, Calif., July 24, 2001 – Abgenix, Inc. (NASDAQ: ABGX) today reported a net loss of \$14.8 million or \$0.17 per share for the quarter ended June 30, 2001, compared to a net loss of \$2.4 million or \$0.03 per share for the quarter ended June 30, 2000. Contract revenues for the current quarter increased to \$8.4 million from \$3.5 million for the same quarter in 2000. Including interest income, total revenues for the current quarter increased to \$16.0 million from \$12.3 million for the same period in 2000.

Abgenix ended the second quarter with approximately \$575.4 million in cash, cash equivalents and short-term investments. In addition, Abgenix holds long-term investments, primarily equity in corporate partners, totaling \$113.9 million.

Recent company highlights included:

- Initiating a Phase II clinical trial of our lead cancer antibody, ABX-EGF, for kidney cancer;
- Expanding our existing technology license agreement with Centocor;
- Entering a new technology license agreement with Biogen;
- Forming a major target access collaboration with MDS Proteomics; and,
- Announcing the advancement into clinical trials by Amgen of a fully human antibody generated with Abgenix's technology.

In addition, Abgenix has already accomplished its year-end goal of generating fully human antibody product candidates to targets for technology license collaborators.

"We continue to make progress in every area of our business," stated R. Scott Greer, chairman and chief executive officer of Abgenix. "We have entered Phase II clinical trials for two potential blockbuster drugs for cancer and inflammation, based on promising data in earlier trials. Construction of our manufacturing facility, with a planned capacity exceeding 100,000 grams per year, is on schedule to be operational by the end of 2002. Our product pipeline continues to build toward our goal of XenoMouse™-derived product candidates in clinical trials for numerous disease indications by the end of 2001. We have formed six new collaborations and expanded five existing relationships so far in 2001."

- Financial Results -

CONSOLIDATED STATEMENTS OF OPERATIONS	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2001	2000	2001	2000
(in thousands except per share data)	(unaudited)		(unaudited)	
Revenues:				
Contract revenues	\$8,354	\$3,478	\$12,530	\$5,400
Interest and other income	7,664	8,781	17,971	13,100
Total revenues	16,018	12,259	30,501	18,500
Costs and Expenses:				
Research and development	25,628	11,912	42,383	19,100
General and administrative	3,131	1,805	6,200	3,300
Amortization of intangible assets	2,046	777	4,093	1,500
Interest expense	0	185	255	300
Total costs and expenses	30,805	14,679	52,931	24,300
Net loss	(\$14,787)	(\$2,420)	(\$22,430)	(\$5,800)
Basic and diluted net loss per share *	(\$0.17)	(\$0.03)	(\$0.26)	(\$0.03)
Shares used in computing basic and diluted net loss per share	85,947	80,545	85,805	77,500

	June 30,	December 31,				
CONSOLIDATED BALANCE SHEETS	2001	2000				
(in thousands)	(unaudited)					
Cash, cash equivalents and marketable securities	\$575,368	\$692,883				
Other current assets	21,832	25,155				
Total current assets	597,200	718,038				
Property and equipment, net	36,425	18,374				
Long-term investments	113,861	79,181				
Intangible assets, net	114,834	117,997				
Deposits & other assets	6,781	3,210				
Total assets	\$869,101	\$936,800				
Deferred revenue	\$4,330	\$6,978				
Other current liabilities	18,278	14,151				
Acquisition liabilities	1,950	75,429				
Total current liabilities	24,558	96,558				
Deferred rent	1,149	567				
Stockholders' equity	843,394	839,675				
Total liabilities and stockholders' equity	\$869,101	\$936,800				
*After giving effect to both of the two-for-one stock splits effective April 6, 2000 and July 7, 2000.						

Abgenix is a biopharmaceutical company focused on the development and commercialization of fully human monoclonal antibody therapies for a variety of diseases. The company's antibody technology platform, which includes XenoMouse™ and XenoMax™ technologies, enables the rapid generation and selection of high affinity, fully human antibody product candidates to essentially any disease target appropriate for antibody therapy. Abgenix leverages its leadership position in human antibody technologies by building a large and diversified product portfolio through the establishment of licensing arrangements with multiple pharmaceutical, biotechnology and genomics companies and through the development of its own internal proprietary products. For more information on Abgenix, visit the company's website at www.abgenix.com.

###